Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of AG2001 in Patients With Acute Bronchitis
Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd
Summary
This is a Phase 3, randomized, double-blind, active-controlled clinical trial designed to evaluate the efficacy and safety of AG2001 in patients with acute bronchitis. The primary objective is to demonstrate the superiority of AG2001 over two active comparators based on the change in Bronchitis Severity Score (BSS) at Day 4.
Official title: A Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2001 in Patients With Acute Bronchitis
Key Details
Gender
All
Age Range
19 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2025-11-01
Completion Date
2026-10-31
Last Updated
2025-09-30
Healthy Volunteers
No
Conditions
Interventions
AG2001
Oral administration, three times daily for 7 days.
AG20011
Oral administration, three times daily for 7 days.
AG20012
Oral administration, three times daily for 7 days.